249 related articles for article (PubMed ID: 37302340)
1. Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds.
Zhang M; Dai X; Xiang Y; Xie L; Sun M; Shi J
Eur J Med Chem; 2023 Oct; 258():115546. PubMed ID: 37302340
[TBL] [Abstract][Full Text] [Related]
2. Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A; Zhulai G
Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
[TBL] [Abstract][Full Text] [Related]
3. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
4. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
5. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
6. A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities.
McManus J; He T; Gavigan JA; Marchand G; Vougier S; Bedel O; Ferrari P; Arrebola R; Gillespy T; Gregory RC; Licht S; Cheng H; Zhang B; Deng G
SLAS Discov; 2018 Mar; 23(3):264-273. PubMed ID: 29336194
[TBL] [Abstract][Full Text] [Related]
7. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
8. Small molecular CD73 inhibitors: Recent progress and future perspectives.
Ge GH; Wang QY; Zhang ZH; Zhang X; Guo S; Zhang TJ; Meng FH
Eur J Med Chem; 2024 Jan; 264():116028. PubMed ID: 38086190
[TBL] [Abstract][Full Text] [Related]
9. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
10. CD39 - A bright target for cancer immunotherapy.
Guo S; Han F; Zhu W
Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD73 to augment cancer immunotherapy.
Roh M; Wainwright DA; Wu JD; Wan Y; Zhang B
Curr Opin Pharmacol; 2020 Aug; 53():66-76. PubMed ID: 32777746
[TBL] [Abstract][Full Text] [Related]
12. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
13. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
[TBL] [Abstract][Full Text] [Related]
14. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
15. The Immune Regulatory Role of Adenosine in the Tumor Microenvironment.
Xing J; Zhang J; Wang J
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834375
[TBL] [Abstract][Full Text] [Related]
16. CD73 in glioblastoma: Where are we now and what are the future directions?
Gelsleichter NE; Azambuja JH; Rubenich DS; Braganhol E
Immunol Lett; 2023; 256-257():20-27. PubMed ID: 36958430
[TBL] [Abstract][Full Text] [Related]
17. Generation and Function of Non-cell-bound CD73 in Inflammation.
Schneider E; Rissiek A; Winzer R; Puig B; Rissiek B; Haag F; Mittrücker HW; Magnus T; Tolosa E
Front Immunol; 2019; 10():1729. PubMed ID: 31404305
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
20. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity.
Losenkova K; Takeda A; Ragauskas S; Cerrada-Gimenez M; Vähätupa M; Kaja S; Paul ML; Schmies CC; Rolshoven G; Müller CE; Sandholm J; Jalkanen S; Kalesnykas G; Yegutkin GG
Cell Mol Life Sci; 2022 Feb; 79(3):152. PubMed ID: 35212809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
